相关临床试验
11
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
4
36.4%
终止
1
9.1%
Unknown
4
36.4%
撤回
2
18.2%
暂无批准数据
- Tampa General Hospital is the first U.S. hospital to sign the "Make Hospital Food Healthier" pledge, committing to serve nutritious, minimally processed meals to patients. - Michelin-star chef Geoffrey Zakarian overhauled the hospital's menu, removing seed oils, sugar, and maltodextrin while introducing fresh, restaurant-quality options. - Hospital officials reported a 53% increase in food quality scores and higher patient meal completion rates following the menu transformation. - HHS Secretary Robert F. Kennedy Jr. announced plans to expand the healthy food initiative to schools and the military nationwide.
- Florida Attorney General James Uthmeier signed an emergency rule placing highly concentrated 7-hydroxymitragynine (7-OH) and related compounds into Schedule I, enabling felony arrests and product seizures. - Florida medical examiners have linked at least 587 overdose deaths to these products since 2013, with Poison Control data showing more than 25% of exposed patients requiring ICU treatment. - The emergency regulations cap restricted chemicals at 1 milligram per gram of solid or per milliliter of liquid, and require any 7-OH product to contain at least 100 times more mitragynine by mass. - Since the rule took effect, the Florida Department of Agriculture and Consumer Services has removed over 23,000 illegal 7-OH packages from retailers statewide.
- Shyam Kottilil, MD, PhD, joins USF Health as vice dean for Clinical Research, bringing decades of experience in chronic viral diseases, liver disease, and virus-associated cancers. - His work contributed to transforming hepatitis C therapy, including studies showing cure in as little as six weeks with oral antivirals and treatment delivery by primary care providers. - USF Health aims to triple clinical research funding over the next decade by expanding trials, industry partnerships, and multidisciplinary research programs. - Early priorities include applying artificial intelligence to improve liver disease surveillance, detect liver cancer earlier, and advance infectious disease monitoring.
- Florida's Sunshine Genetics Newborn Screening Program will use whole-genome sequencing to screen newborns for nearly 900 rare genetic conditions, compared to the 60 conditions currently screened via standard heel-prick tests. - The pilot launches this summer at Tampa General Hospital, with planned expansion to Orlando and Miami, then statewide over five years. - Early diagnosis through genome sequencing can reduce the average five-year diagnostic odyssey, which costs over $500,000 per child, and enable early interventions including gene therapy before symptoms manifest. - The program is supported by the Sunshine Genetics Act, the Florida Institute for Pediatric Rare Diseases at FSU, and industry partner GeneDx, with strong genetic privacy protections under Florida law.
- Microbot Medical has commenced full market release of its LIBERTY Endovascular Robotic System at the Society of Interventional Radiology conference after successful limited market adoption by multiple healthcare systems including Emory Healthcare and Tampa General Hospital. - The LIBERTY system represents the only FDA-cleared, single-use, remotely operated robotic platform for peripheral endovascular procedures, demonstrating versatility across multiple procedure types including prostate artery embolization and uterine fibroid embolization. - The company has expanded its commercial infrastructure from four to eight sales territories with plans to reach 12 territories by end of 2026, while recent peer-reviewed publication in the Journal of Vascular and Interventional Radiology validates the system's clinical efficacy.
- Medical Microinstruments (MMI) received FDA 510(k) clearance for NanoWrist Scissors and Forceps, enabling the world's first fully robotic-assisted microsurgical operation from incision to closure. - The American Medical Association issued a new CPT code (1019T) for lymphovenous bypass surgery, with CMS finalizing payment rates effective January 1, 2026. - Tampa General Hospital completed the first U.S. clinical use of the cleared dissection instruments in a lymphovenous bypass procedure for lymphedema treatment. - These developments address significant barriers to microsurgical adoption by providing both technical feasibility through robotic precision and economic viability through established reimbursement pathways.
- Multiple studies presented at MAD-ID 2025 demonstrate fidaxomicin's superior efficacy over vancomycin in preventing C. difficile infection recurrence among high-risk patient populations. - A multicenter retrospective study of 176 hospitalized adults showed fidaxomicin reduced 90-day recurrence rates by 68.3% compared to vancomycin (7.9% vs 19%). - Immunocompromised patients, including solid organ transplant recipients and chemotherapy patients, experienced significantly lower 28-day recurrence rates with fidaxomicin (5% vs 30%). - Despite clinical benefits and updated guidelines recommending fidaxomicin, adoption remains limited due to cost barriers and formulary restrictions.
- Innovative catheter-based treatments for tricuspid regurgitation are providing new options for patients deemed too high-risk for traditional open-heart surgery, with procedures allowing discharge within 2-3 days. - The Evoque Tricuspid Valve Replacement System, FDA-approved in 2024, is being implemented at Sarasota Memorial Hospital, while Tampa General Hospital completed Florida's first TricValve procedure under an FDA Early Feasibility Study. - Approximately 1.6 million Americans suffer from tricuspid regurgitation, which can lead to heart failure and other life-threatening complications if left untreated with limited options previously available.
- New research from the DiVERT Stroke clinical study shows women experiencing stroke receive significantly fewer cardiology referrals and shorter hospital stays compared to men. - Analysis of 2,699 patients reveals female patients were less likely to receive post-stroke cardiac monitoring (19.9% vs 23%) despite women having a higher lifetime stroke risk. - The study demonstrates consistent atrial fibrillation detection rates post-stroke with cardiac monitoring across both genders, highlighting the importance of standardized care pathways.
• Amivantamab plus chemotherapy was approved for EGFR exon 19 deletions or exon 21 L858R substitution mutations in advanced NSCLC after progression on EGFR TKIs. • Perioperative durvalumab and nivolumab have been approved for resectable NSCLC, expanding treatment options for patients without EGFR or ALK alterations. • Fam-trastuzumab deruxtecan-nxki (T-DXd) is emerging as a significant option for HER2-mutated NSCLC, potentially shifting to frontline settings. • Ongoing research explores optimizing checkpoint inhibitor use in the perioperative setting, particularly for patients achieving complete pathologic response.
